STOCK TITAN

Si-Bone - SIBN STOCK NEWS

Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.

Si-Bone, Inc. (SIBN) is a leader in minimally invasive surgical solutions for sacroiliac joint disorders, pioneering orthopedic innovations since its founding. This news hub provides investors and healthcare professionals with essential updates on the company's progress in medical device development and market expansion.

Comprehensive SIBN Coverage: Access official press releases and third-party analysis covering regulatory milestones, quarterly earnings, product launches (including iFuse System updates), clinical trial results, and strategic partnerships. Our curated feed eliminates speculation to deliver actionable information about this NASDAQ-listed innovator.

Strategic Insights: Track SIBN's advancements in sacroiliac joint fusion technology alongside broader industry trends in orthopedic devices. Discover how patented titanium implants and FDA-cleared systems position the company within competitive medical sectors.

Bookmark this page for real-time updates on SIBN's financial performance, surgical innovation developments, and leadership in addressing underdiagnosed pelvic health conditions through clinically validated solutions.

Rhea-AI Summary

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, after market close. The company will hold a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.

Investors can participate in the conference call by registering through the provided link. The webcast will be accessible through the company's website's 'Investors' section and will remain available for replay for at least 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences earnings
-
Rhea-AI Summary

SI-BONE (SIBN) reported strong Q4 2024 financial results with worldwide revenue reaching $49.0 million, up 26% year-over-year. U.S. revenue grew 28% to $46.9 million. The company achieved positive adjusted EBITDA of $1.9 million in Q4, a 139% improvement.

For full-year 2024, worldwide revenue increased 20% to $167.2 million, with U.S. revenue up 21% to $158.4 million. The company reduced its net loss by 29% to $30.9 million. Gross margin remained stable at 79%.

Looking ahead, SI-BONE provided 2025 guidance, projecting worldwide revenue between $193.5-$195.5 million, representing 16-17% growth. The company expects to achieve positive adjusted EBITDA for both second half and full year 2025, with gross margins forecasted at 77-78%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
-
Rhea-AI Summary

SI-BONE (SIBN) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.

Investors can participate in the conference call by registering through the provided link. The webcast will be available on the company's investor relations website and will remain accessible for replay for at least 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
conferences earnings
Rhea-AI Summary

SI-BONE (SIBN) has released preliminary Q4 2024 financial results, showing strong growth across key metrics. The company reported Q4 worldwide revenue between $48.8-$49.0 million, representing approximately 26% growth year-over-year. U.S. revenue reached $46.7-$46.9 million, up about 28%.

For the full year 2024, worldwide revenue was between $167.0-$167.1 million, showing 20% growth, while U.S. revenue reached $158.2-$158.4 million, up 21%. The company expanded its U.S. active physician base to approximately 1,390, representing 23% growth. SI-BONE ended Q4 with approximately $150 million in cash and marketable securities, with net cash use of about $0.8 million in the quarter. Notably, the company achieved adjusted EBITDA profitability in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.29%
Tags
none
-
Rhea-AI Summary

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Piper Sandler Healthcare Conference in New York. The company's management will conduct a fireside chat on December 4, 2024, at 11:00 a.m. ET / 8:00 a.m. PT.

Investors can access the conference call through a registration link, and the live audio webcast will be available on the company's website's 'Investors' section. The webcast recording will remain accessible for replay for at least 90 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
-
Rhea-AI Summary

SI-BONE reported Q3 2024 financial results with worldwide revenue of $40.3 million, up 19% year-over-year. U.S. revenue grew 18% to $38.3 million, with gross margin at 79%. The company reduced its net loss by 34% to $6.6 million and improved Adjusted EBITDA loss by 94% to $0.2 million. Notable achievements include reaching over 1,200 U.S. active physicians (15% increase) and commercializing iFuse TORQ TNT. The company updated its 2024 worldwide revenue guidance to $165-166 million and expects to achieve positive Adjusted EBITDA in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.93%
Tags
Rhea-AI Summary

SI-BONE (Nasdaq: SIBN) has received Transitional Pass-Through (TPT) payment status from CMS for its iFuse Bedrock Granite™ system, effective January 1, 2025, for up to three years. This innovative technology, used for pelvic fixation and sacroiliac joint fusion during lumbar spinal fusion procedures, will receive additional payment support without device offset in outpatient settings. The Granite system, which received FDA clearance in May 2022 and Breakthrough Device Designation in November 2021, addresses a market of approximately 130,000 annual lumbar spinal fusion procedures ending at the pelvis in the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
none
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced that it will release its third quarter 2024 financial results after the market closes on Tuesday, November 12, 2024. Following the release, the company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results.

Investors interested in participating in the conference call can register using the provided link. Additionally, a live audio webcast will be available on the 'Investors' section of SI-BONE's website. The webcast will be archived and accessible for replay for at least 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences earnings
-
Rhea-AI Summary

SI-BONE, a medical device company focused on sacropelvic disorders, announced the first-in-patient procedures with their FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). This innovative system, which received 510(k) clearance in August 2024, addresses the challenges of pelvic fragility fractures in patients with poor bone quality. The TNT implant features a pelvis-specific design for improved fixation and reduced screw backout risk, and it is the first 3D-printed transiliac-transsacral screw cleared for market use in the U.S. Surgeons praised its streamlined instrumentation and efficient implantation process, which minimizes operating time and enhances patient recovery. SI-BONE’s CEO, Laura Francis, highlighted the system's potential to meet the unmet clinical needs of complex pelvic fractures and expand their leadership in the sacropelvic space.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
Rhea-AI Summary

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will host a fireside chat on September 4, 2024, at 10:45 a.m. Eastern Time.

Investors can listen to the conference call by registering through a provided link. The webcast will be available live on the 'Investors' section of SI-BONE's website and will be archived for at least 90 days after the event. This presentation offers an opportunity for investors to gain insights into SI-BONE's operations and future prospects in the medical device industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.07%
Tags
conferences
Si-Bone

Nasdaq:SIBN

SIBN Rankings

SIBN Stock Data

565.90M
37.46M
3.09%
95.51%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA